Prevalence and Organ Distribution of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Among Decedents in New Mexico

Overview

Journal Amyloid

Specialty Biochemistry

Date 2016 Feb 26

PMID 26912093

Citations 15

Authors

Christopher P Larsen

Marjorie L Beggs

Jon D Wilson

Sarah L Lathrop

Affiliations

Soon will be listed here.

Abstract

Leukocyte chemotactic factor 2 (LECT2) amyloidosis is one of the most recently described types of amyloidosis. Since its description, it has been found to be one the most common types of amyloidosis in large series of amyloid cases involving the kidney and liver in the United States, where it primarily affects patients of Hispanic ethnicity. We sought to investigate the prevalence of this disease among Hispanic adult decedents who had an autopsy performed at the New Mexico Office of the Medical Investigator and determine the organ distribution of amyloid deposition. LECT2 amyloid deposits were identified within the kidney in 3.1% of Hispanic decedents. It was consistently deposited in the liver, spleen, adrenals, and lungs but did not involve the myocardium or brain. LECT2 amyloidosis is likely not rare among Hispanics in the Southwest United States and could represent an important but under-recognized etiology of chronic kidney disease in this population.

Citing Articles

Regional hotspots for chronic kidney disease: A multinational study from the ISN-GKHA.

Garcia P, Strasma A, Wijewickrama E, Arruebo S, Caskey F, Damster S PLOS Glob Public Health. 2024; 4(12):e0004014.

PMID: 39636884 PMC: 11620454. DOI: 10.1371/journal.pgph.0004014.

Amyloidosis in Childhood: A Review of Clinical Features and Comparison with Adult Forms.

Zamarra G, Sandu M, Caione N, Di Pasquale G, Di Berardino A, Di Ludovico A J Clin Med. 2024; 13(22).

PMID: 39597824 PMC: 11594867. DOI: 10.3390/jcm13226682.

Advancing Renal Amyloidosis Care: The Role of Modern Diagnostic Techniques with the Potential of Enhancing Patient Outcomes.

Delrue C, Dendooven A, Vandendriessche A, Speeckaert R, De Bruyne S, Speeckaert M Int J Mol Sci. 2024; 25(11).

PMID: 38892061 PMC: 11172584. DOI: 10.3390/ijms25115875.

Global research trends and hotspots for leukocyte cell-derived chemotaxin-2 from the past to 2023: a combined bibliometric review.

Liu W, Wang Q, Yeerlan J, Yan Y, Xu L, Jia C Front Immunol. 2024; 15:1413466.

PMID: 38881894 PMC: 11176436. DOI: 10.3389/fimmu.2024.1413466.

ALECT2 amyloidosis with concurrent IgG4-related interstitial nephritis, membranous nephropathy and diabetic kidney disease: a case report and literature review.

Shaheen M, Bharat A, Friedman A, Guo S J Nephrol. 2024; 37(8):2363-2369.

PMID: 38630340 DOI: 10.1007/s40620-024-01924-9.

References

Mereuta O, Theis J, Vrana J, Law M, Grogg K, Dasari S . Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. Blood. 2014; 123(10):1479-82. DOI: 10.1182/blood-2013-07-517938. View

BUCK F, Koss M, Sherrod A, Wu A, Takahashi M . Ethnic distribution of amyloidosis: an autopsy study. Mod Pathol. 1989; 2(4):372-7. View

Larsen C . Leukocyte chemotactic factor 2 amyloidosis can be reliably diagnosed by immunohistochemical staining. Hum Pathol. 2014; 45(10):2179. DOI: 10.1016/j.humpath.2014.06.024. View

Sipe J, Benson M, Buxbaum J, Ikeda S, Merlini G, Saraiva M . Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014; 21(4):221-4. DOI: 10.3109/13506129.2014.964858. View

Said S, Sethi S, Valeri A, Leung N, Cornell L, Fidler M . Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013; 8(9):1515-23. PMC: 3805078. DOI: 10.2215/CJN.10491012. View

Angell T, Swaika A, Sood N, Goldfarb M, Siddiqi I, Ailawadhi S . Localized LECT2 amyloidosis of the adrenal gland with coexisting MGUS: a diagnostic challenge. Ann Hematol. 2015; 94(9):1603-4. DOI: 10.1007/s00277-015-2419-7. View

Nasr S, Dogan A, Larsen C . Leukocyte Cell-Derived Chemotaxin 2-Associated Amyloidosis: A Recently Recognized Disease with Distinct Clinicopathologic Characteristics. Clin J Am Soc Nephrol. 2015; 10(11):2084-93. PMC: 4633801. DOI: 10.2215/CJN.12551214. View

von Hutten H, Mihatsch M, Lobeck H, Rudolph B, Eriksson M, Rocken C . Prevalence and origin of amyloid in kidney biopsies. Am J Surg Pathol. 2009; 33(8):1198-205. DOI: 10.1097/PAS.0b013e3181abdfa7. View

Khalighi M, Yue A, Hwang M, Wallace W . Leukocyte chemotactic factor 2 (LECT2) amyloidosis presenting as pulmonary-renal syndrome: a case report and review of the literature. Clin Kidney J. 2015; 6(6):618-21. PMC: 4438374. DOI: 10.1093/ckj/sft126. View

10.

Said S, Sethi S, Valeri A, Chang A, Nast C, Krahl L . Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney Int. 2014; 86(2):370-7. DOI: 10.1038/ki.2013.558. View

11.

Benson M, James S, Scott K, Liepnieks J, Kluve-Beckerman B . Leukocyte chemotactic factor 2: A novel renal amyloid protein. Kidney Int. 2008; 74(2):218-22. DOI: 10.1038/ki.2008.152. View

12.

Larsen C, Walker P, Weiss D, Solomon A . Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies. Kidney Int. 2010; 77(9):816-9. PMC: 11181467. DOI: 10.1038/ki.2010.9. View

13.

Larsen C, Kossmann R, Beggs M, Solomon A, Walker P . Clinical, morphologic, and genetic features of renal leukocyte chemotactic factor 2 amyloidosis. Kidney Int. 2014; 86(2):378-82. DOI: 10.1038/ki.2014.11. View

14.

Chandan V, Shah S, Lam-Himlin D, De Petris G, Mereuta O, Dogan A . Globular hepatic amyloid is highly sensitive and specific for LECT2 amyloidosis. Am J Surg Pathol. 2015; 39(4):558-64. DOI: 10.1097/PAS.0000000000000373. View